table of content
1 Study Coverage
1.1 Prophylactic HIV Drug Product Introduction
1.2 Market by Type
1.2.1 Global Prophylactic HIV Drug Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
1.2.2 Nucleoside or Nucleotide Reverse Transcriptase Inhibitors (NRTI)
1.2.3 Integrase Inhibitor
1.3 Market by Application
1.3.1 Global Prophylactic HIV Drug Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 Hospital Pharmacy
1.3.3 Retail Pharmacy
1.3.4 Online Pharmacy
1.4 Study Objectives
1.5 Years Considered
2 Executive Summary
2.1 Global Prophylactic HIV Drug Sales Estimates and Forecasts 2017-2028
2.2 Global Prophylactic HIV Drug Revenue Estimates and Forecasts 2017-2028
2.3 Global Prophylactic HIV Drug Revenue by Region: 2017 VS 2021 VS 2028
2.4 Global Prophylactic HIV Drug Sales by Region
2.4.1 Global Prophylactic HIV Drug Sales by Region (2017-2022)
2.4.2 Global Sales Prophylactic HIV Drug by Region (2023-2028)
2.5 Global Prophylactic HIV Drug Revenue by Region
2.5.1 Global Prophylactic HIV Drug Revenue by Region (2017-2022)
2.5.2 Global Prophylactic HIV Drug Revenue by Region (2023-2028)
2.6 North America
2.7 Europe
2.8 Asia-Pacific
2.9 Latin America
2.10 Middle East & Africa
3 Competition by Manufacturers
3.1 Global Prophylactic HIV Drug Sales by Manufacturers
3.1.1 Global Top Prophylactic HIV Drug Manufacturers by Sales (2017-2022)
3.1.2 Global Prophylactic HIV Drug Sales Market Share by Manufacturers (2017-2022)
3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Prophylactic HIV Drug in 2021
3.2 Global Prophylactic HIV Drug Revenue by Manufacturers
3.2.1 Global Prophylactic HIV Drug Revenue by Manufacturers (2017-2022)
3.2.2 Global Prophylactic HIV Drug Revenue Market Share by Manufacturers (2017-2022)
3.2.3 Global Top 10 and Top 5 Companies by Prophylactic HIV Drug Revenue in 2021
3.3 Global Prophylactic HIV Drug Sales Price by Manufacturers (2017-2022)
3.4 Analysis of Competitive Landscape
3.4.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Prophylactic HIV Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4.3 Global Prophylactic HIV Drug Manufacturers Geographical Distribution
3.5 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
4.1 Global Prophylactic HIV Drug Sales by Type
4.1.1 Global Prophylactic HIV Drug Historical Sales by Type (2017-2022)
4.1.2 Global Prophylactic HIV Drug Forecasted Sales by Type (2023-2028)
4.1.3 Global Prophylactic HIV Drug Sales Market Share by Type (2017-2028)
4.2 Global Prophylactic HIV Drug Revenue by Type
4.2.1 Global Prophylactic HIV Drug Historical Revenue by Type (2017-2022)
4.2.2 Global Prophylactic HIV Drug Forecasted Revenue by Type (2023-2028)
4.2.3 Global Prophylactic HIV Drug Revenue Market Share by Type (2017-2028)
4.3 Global Prophylactic HIV Drug Price by Type
4.3.1 Global Prophylactic HIV Drug Price by Type (2017-2022)
4.3.2 Global Prophylactic HIV Drug Price Forecast by Type (2023-2028)
5 Market Size by Application
5.1 Global Prophylactic HIV Drug Sales by Application
5.1.1 Global Prophylactic HIV Drug Historical Sales by Application (2017-2022)
5.1.2 Global Prophylactic HIV Drug Forecasted Sales by Application (2023-2028)
5.1.3 Global Prophylactic HIV Drug Sales Market Share by Application (2017-2028)
5.2 Global Prophylactic HIV Drug Revenue by Application
5.2.1 Global Prophylactic HIV Drug Historical Revenue by Application (2017-2022)
5.2.2 Global Prophylactic HIV Drug Forecasted Revenue by Application (2023-2028)
5.2.3 Global Prophylactic HIV Drug Revenue Market Share by Application (2017-2028)
5.3 Global Prophylactic HIV Drug Price by Application
5.3.1 Global Prophylactic HIV Drug Price by Application (2017-2022)
5.3.2 Global Prophylactic HIV Drug Price Forecast by Application (2023-2028)
6 North America
6.1 North America Prophylactic HIV Drug Market Size by Type
6.1.1 North America Prophylactic HIV Drug Sales by Type (2017-2028)
6.1.2 North America Prophylactic HIV Drug Revenue by Type (2017-2028)
6.2 North America Prophylactic HIV Drug Market Size by Application
6.2.1 North America Prophylactic HIV Drug Sales by Application (2017-2028)
6.2.2 North America Prophylactic HIV Drug Revenue by Application (2017-2028)
6.3 North America Prophylactic HIV Drug Market Size by Country
6.3.1 North America Prophylactic HIV Drug Sales by Country (2017-2028)
6.3.2 North America Prophylactic HIV Drug Revenue by Country (2017-2028)
6.3.3 U.S.
6.3.4 Canada
7 Europe
7.1 Europe Prophylactic HIV Drug Market Size by Type
7.1.1 Europe Prophylactic HIV Drug Sales by Type (2017-2028)
7.1.2 Europe Prophylactic HIV Drug Revenue by Type (2017-2028)
7.2 Europe Prophylactic HIV Drug Market Size by Application
7.2.1 Europe Prophylactic HIV Drug Sales by Application (2017-2028)
7.2.2 Europe Prophylactic HIV Drug Revenue by Application (2017-2028)
7.3 Europe Prophylactic HIV Drug Market Size by Country
7.3.1 Europe Prophylactic HIV Drug Sales by Country (2017-2028)
7.3.2 Europe Prophylactic HIV Drug Revenue by Country (2017-2028)
7.3.3 Germany
7.3.4 France
7.3.5 U.K.
7.3.6 Italy
7.3.7 Russia
8 Asia Pacific
8.1 Asia Pacific Prophylactic HIV Drug Market Size by Type
8.1.1 Asia Pacific Prophylactic HIV Drug Sales by Type (2017-2028)
8.1.2 Asia Pacific Prophylactic HIV Drug Revenue by Type (2017-2028)
8.2 Asia Pacific Prophylactic HIV Drug Market Size by Application
8.2.1 Asia Pacific Prophylactic HIV Drug Sales by Application (2017-2028)
8.2.2 Asia Pacific Prophylactic HIV Drug Revenue by Application (2017-2028)
8.3 Asia Pacific Prophylactic HIV Drug Market Size by Region
8.3.1 Asia Pacific Prophylactic HIV Drug Sales by Region (2017-2028)
8.3.2 Asia Pacific Prophylactic HIV Drug Revenue by Region (2017-2028)
8.3.3 China
8.3.4 Japan
8.3.5 South Korea
8.3.6 India
8.3.7 Australia
8.3.8 Taiwan
8.3.9 Indonesia
8.3.10 Thailand
8.3.11 Malaysia
8.3.12 Philippines
9 Latin America
9.1 Latin America Prophylactic HIV Drug Market Size by Type
9.1.1 Latin America Prophylactic HIV Drug Sales by Type (2017-2028)
9.1.2 Latin America Prophylactic HIV Drug Revenue by Type (2017-2028)
9.2 Latin America Prophylactic HIV Drug Market Size by Application
9.2.1 Latin America Prophylactic HIV Drug Sales by Application (2017-2028)
9.2.2 Latin America Prophylactic HIV Drug Revenue by Application (2017-2028)
9.3 Latin America Prophylactic HIV Drug Market Size by Country
9.3.1 Latin America Prophylactic HIV Drug Sales by Country (2017-2028)
9.3.2 Latin America Prophylactic HIV Drug Revenue by Country (2017-2028)
9.3.3 Mexico
9.3.4 Brazil
9.3.5 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Prophylactic HIV Drug Market Size by Type
10.1.1 Middle East and Africa Prophylactic HIV Drug Sales by Type (2017-2028)
10.1.2 Middle East and Africa Prophylactic HIV Drug Revenue by Type (2017-2028)
10.2 Middle East and Africa Prophylactic HIV Drug Market Size by Application
10.2.1 Middle East and Africa Prophylactic HIV Drug Sales by Application (2017-2028)
10.2.2 Middle East and Africa Prophylactic HIV Drug Revenue by Application (2017-2028)
10.3 Middle East and Africa Prophylactic HIV Drug Market Size by Country
10.3.1 Middle East and Africa Prophylactic HIV Drug Sales by Country (2017-2028)
10.3.2 Middle East and Africa Prophylactic HIV Drug Revenue by Country (2017-2028)
10.3.3 Turkey
10.3.4 Saudi Arabia
11 Company Profiles
11.1 Gilead Sciences
11.1.1 Gilead Sciences Corporation Information
11.1.2 Gilead Sciences Overview
11.1.3 Gilead Sciences Prophylactic HIV Drug Sales, Price, Revenue and Gross Margin (2017-2022)
11.1.4 Gilead Sciences Prophylactic HIV Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.1.5 Gilead Sciences Recent Developments
11.2 Merck
11.2.1 Merck Corporation Information
11.2.2 Merck Overview
11.2.3 Merck Prophylactic HIV Drug Sales, Price, Revenue and Gross Margin (2017-2022)
11.2.4 Merck Prophylactic HIV Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.2.5 Merck Recent Developments
11.3 Mylan
11.3.1 Mylan Corporation Information
11.3.2 Mylan Overview
11.3.3 Mylan Prophylactic HIV Drug Sales, Price, Revenue and Gross Margin (2017-2022)
11.3.4 Mylan Prophylactic HIV Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.3.5 Mylan Recent Developments
11.4 Cipla
11.4.1 Cipla Corporation Information
11.4.2 Cipla Overview
11.4.3 Cipla Prophylactic HIV Drug Sales, Price, Revenue and Gross Margin (2017-2022)
11.4.4 Cipla Prophylactic HIV Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.4.5 Cipla Recent Developments
11.5 Bristol-Myers Squibb
11.5.1 Bristol-Myers Squibb Corporation Information
11.5.2 Bristol-Myers Squibb Overview
11.5.3 Bristol-Myers Squibb Prophylactic HIV Drug Sales, Price, Revenue and Gross Margin (2017-2022)
11.5.4 Bristol-Myers Squibb Prophylactic HIV Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.5.5 Bristol-Myers Squibb Recent Developments
11.6 Roche
11.6.1 Roche Corporation Information
11.6.2 Roche Overview
11.6.3 Roche Prophylactic HIV Drug Sales, Price, Revenue and Gross Margin (2017-2022)
11.6.4 Roche Prophylactic HIV Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.6.5 Roche Recent Developments
12 Industry Chain and Sales Channels Analysis
12.1 Prophylactic HIV Drug Industry Chain Analysis
12.2 Prophylactic HIV Drug Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Prophylactic HIV Drug Production Mode & Process
12.4 Prophylactic HIV Drug Sales and Marketing
12.4.1 Prophylactic HIV Drug Sales Channels
12.4.2 Prophylactic HIV Drug Distributors
12.5 Prophylactic HIV Drug Customers
13 Market Drivers, Opportunities, Challenges and Risks Factors Analysis
13.1 Prophylactic HIV Drug Industry Trends
13.2 Prophylactic HIV Drug Market Drivers
13.3 Prophylactic HIV Drug Market Challenges
13.4 Prophylactic HIV Drug Market Restraints
14 Key Findings in The Global Prophylactic HIV Drug Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer
